Photoactivatable oncolytic adenovirus for optogenetic cancer therapy.
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
23 07 2020
23 07 2020
Historique:
received:
11
12
2019
accepted:
13
07
2020
revised:
11
07
2020
entrez:
25
7
2020
pubmed:
25
7
2020
medline:
26
3
2021
Statut:
epublish
Résumé
Virotherapy using oncolytic adenovirus is an effective anticancer strategy. However, the tumor selectivity of oncolytic adenoviruses is not enough high. To develop oncolytic adenovirus with a low risk of off-tumor toxicity, we constructed a photoactivatable oncolytic adenovirus (paOAd). In response to blue light irradiation, the expression of adenoviral E1 genes, which are necessary for adenoviral replication, is induced and replication of this adenovirus occurs. In vitro, efficient lysis of various human cancer cell lines was observed by paOAd infection followed by blue light irradiation. Importantly, there was no off-tumor toxicity unless the cells were irradiated by blue light. In vivo, tumor growth in a subcutaneous tumor model and a mouse model of liver cancer was significantly inhibited by paOAd infection followed by blue light irradiation. In addition, paOAd also showed a therapeutic effect on cancer stem cells. These results suggest that paOAd is useful as a safe and therapeutically effective cancer therapy.
Identifiants
pubmed: 32703933
doi: 10.1038/s41419-020-02782-6
pii: 10.1038/s41419-020-02782-6
pmc: PMC7378209
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
570Références
Fergusson, D. A. et al. Assessing the completeness of reporting in preclinical oncolytic virus therapy studies. Mol. Ther. Oncolytics14, 179–187 (2019).
doi: 10.1016/j.omto.2019.05.004
Mizuguchi, H. & Kay, M. A. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum. Gene Ther.9, 2577–2583 (1998).
doi: 10.1089/hum.1998.9.17-2577
Mizuguchi, H. & Kay, M. A. A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. Hum. Gene Ther.10, 2013–2017 (1999).
doi: 10.1089/10430349950017374
Kawashima, T. et al. Telomerase-specific replication-selective virotherapy for human cancer. Clin. Cancer Res.10, 285–292 (2004).
doi: 10.1158/1078-0432.CCR-1075-3
Machitani, M. et al. Enhanced oncolytic activities of the telomerase-specific replication-competent adenovirus expressing short-hairpin RNA against dicer. Mol. Cancer Ther.16, 251–259 (2017).
doi: 10.1158/1535-7163.MCT-16-0383
Negoro, R. et al. Efficient generation of small intestinal epithelial-like cells from human iPSCs for drug absorption and metabolism studies. Stem Cell Rep.11, 1539–1550 (2018).
doi: 10.1016/j.stemcr.2018.10.019
Takayama, K. et al. Generation of human iPSC–derived intestinal epithelial cell monolayers by CDX2 transduction. Cell. Mol. Gastroenterol. Hepatol.8, 513–526 (2019).
doi: 10.1016/j.jcmgh.2019.06.004
Shimizu, K., Sakurai, F., Machitani, M., Katayama, K. & Mizuguchi, H. Quantitative analysis of the leaky expression of adenovirus genes in cells transduced with a replication-incompetent adenovirus vector. Mol. Pharm.8, 1430–1435 (2011).
doi: 10.1021/mp200121z
Takayama, K. & Mizuguchi, H. Generation of optogenetically modified adenovirus vector for spatiotemporally controllable gene therapy. ACS Chem. Biol.13, 449–454 (2018).
doi: 10.1021/acschembio.7b01058
Wang, X., Chen, X. & Yang, Y. Spatiotemporal control of gene expression by a light-switchable transgene system. Nat. Methods9, 266–269 (2012).
doi: 10.1038/nmeth.1892
Clevers, H. The cancer stem cell: premises, promises and challenges. Nat. Med.17, 313 (2011).
doi: 10.1038/nm.2304
Chaurasiya, S., Chen, N. & Warner, S. Oncolytic virotherapy versus cancer stem cells: a review of approaches and mechanisms. Cancers10, 124 (2018).
doi: 10.3390/cancers10040124
Zhang, X., Komaki, R., Wang, L., Fang, B. & Chang, J. Y. Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus. Clin. Cancer Res.14, 2813–2823 (2008).
doi: 10.1158/1078-0432.CCR-07-1528
Chen, S. et al. Near-infrared deep brain stimulation via upconversion nanoparticle-mediated optogenetics. Science359, 679–684 (2018).
doi: 10.1126/science.aaq1144
Chavez, A. et al. Comparison of Cas9 activators in multiple species. Nat. Methods13, 563–567 (2016).
doi: 10.1038/nmeth.3871
Kawano, F., Suzuki, H., Furuya, A. & Sato, M. Engineered pairs of distinct photoswitches for optogenetic control of cellular proteins. Nat. Commun.6, 6256 (2015).
doi: 10.1038/ncomms7256
Iwahori, K. et al. Overexpression of SOCS3 exhibits preclinical antitumor activity against malignant pleural mesothelioma. Int. J. Cancer129, 993–1005 (2011).
doi: 10.1002/ijc.25716
Iwahori, K. et al. SOCS‐1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma. Int. J. Cancer132, 459–471 (2013).
doi: 10.1002/ijc.27611
Polstein, L. R. & Gersbach, C. A. A light-inducible CRISPR-Cas9 system for control of endogenous gene activation. Nat. Chem. Biol.11, 198–200 (2015).
doi: 10.1038/nchembio.1753
Nihongaki, Y. et al. CRISPR-Cas9-based photoactivatable transcription systems to induce neuronal differentiation. Nat. Methods14, 963–966 (2017).
doi: 10.1038/nmeth.4430